Publications by authors named "Mervyn Israel"

Claim this Profile
E
Enhanced solubility and functionality of valrubicin (AD-32) against cancer cells upon encapsulation into biocompatible nanoparticles.
Nirupama Sabnis, Maya Nair, Mervyn Israel, Walter J McConathy, Andras G Lacko

Int J Nanomedicine· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
N-Benzyladriamycin-14-valerate (AD 198): a non-cardiotoxic anthracycline that is cardioprotective through PKC-epsilon activation.
Polly A Hofmann, Mervyn Israel, Yoshihiro Koseki, Jeffrey Laskin, Joshua Gray

J Pharmacol Exp Ther· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
N-benzyladriamycin-14-valerate (AD 198) activates protein kinase C-delta holoenzyme to trigger mitochondrial depolarization and cytochrome c release independently of permeability transition pore opening and Ca2+ influx.
Leonard Lothstein, Luydmila Savranskaya, Christina M Barrett, Mervyn Israel, Trevor W Sweatman

Anticancer Drugs· June 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circumvention of nuclear factor kappaB-induced chemoresistance by cytoplasmic-targeted anthracyclines.
Jennifer D Bilyeu, Ganesh R Panta, Lakita G Cavin, Christina M Barrett, Eddie J Turner, Mervyn Israel

Mol Pharmacol· April 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ATM and the catalytic subunit of DNA-dependent protein kinase activate NF-kappaB through a common MEK/extracellular signal-regulated kinase/p90(rsk) signaling pathway in response to distinct forms of DNA damage.
Ganesh R Panta, Swayamjot Kaur, Lakita G Cavin, Maria L Cortés, Frank Mercurio, Mervyn Israel

Mol Cell Biol· March 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel extranuclear-targeted anthracyclines override the antiapoptotic functions of Bcl-2 and target protein kinase C pathways to induce apoptosis.
Christina M Barrett, Felicia L Lewis, J Brent Roaten, Trevor W Sweatman, Mervyn Israel

Mol Cancer Ther· May 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interaction of the novel anthracycline antitumor agent N-benzyladriamycin-14-valerate with the C1-regulatory domain of protein kinase C: structural requirements, isoform specificity, and correlation with drug cytotoxicity.
J Brent Roaten, Marcelo G Kazanietz, Maria Jose Caloca, Paul J Bertics, Leonard Lothstein, Mervyn Israel

Mol Cancer Ther· May 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis